Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014)

•All tested S. aureus were susceptible to oritavancin, with MIC50/90 values of 0.03/0.06 μg/mL.•The activity of oritavancin was not adversely affected when tested against MRSA, MSSA, CA, HA, or MDR isolates.•Overall, oritavancin MIC50 and MIC90 results were 8-fold lower than those of daptomycin and 16-32-fold lower than those of vancomycin or linezolid.

Oritavancin has been approved in the United States and European Union for the treatment of acute bacterial skin and skin structure infections caused by several Gram-positive pathogens including Staphylococcus aureus. In this study, the in vitro activity of oritavancin and comparator agents was assessed against 1008 isolates of contemporary invasive community- or healthcare-associated S. aureus (790 and 218 isolates, respectively). All sampled contemporary (2013-2014) S. aureus isolates were susceptible at ≤0.12 μg/mL to oritavancin (MIC50/90 values, 0.03/0.06 μg/mL), regardless of origin or susceptibility phenotype.